Abstract:Phosphoinositide 3-kinase alpha (PI3Kα) is one of the most frequently dysregulated kinases known for their pivotal role in many oncogenic diseases. While the side effects linked to existing drugs against PI3Kα-induced cancers provide an avenue for further research, the significant structural conservation among PI3Ks makes it extremely difficult to develop new isoform-selective PI3Kα inhibitors. Embracing this challenge, we herein designed a hybrid protocol by integrating machine learning (ML) with in silico drug-designing strategies. A deep learning classification model was developed and trained on the physicochemical descriptors data of known PI3Kα inhibitors and used as a screening filter for a database of small molecules. This approach led us to the prediction of 662 compounds showcasing appropriate features to be considered as PI3Kα inhibitors. Subsequently, a multiphase molecular docking was applied to further characterize the predicted hits in terms of their binding affinities and binding modes in the targeted cavity of the PI3Kα. As a result, a total of 12 compounds were identified whereas the best poses highlighted the efficiency of these ligands in maintaining interactions with the crucial residues of the protein to be targeted for the inhibition of associated activity. Notably, potential activity of compound 12 in counteracting PI3Kα function was found in a previous in vitro study. Following the drug-likeness and pharmacokinetic characterizations, six compounds (compounds 1 , 2 , 3 , 6 , 7, and 11) with suitable ADME-T profiles and promising bioavailability were selected. The mechanistic studies in dynamic mode further endorsed the potential of identified hits in blocking the ATP-binding site of the receptor with higher binding affinities than the native inhibitor, alpelisib (BYL-719), particularly the compounds 1 , 2, and 11. These outcomes support the reliability of the developed classification model and the devised computational strategy for identifying new isoform-selective drug candidates for PI3Kα inhibition.

Structural basis for tailor-made selective PI3K α/β inhibitors: a computational perspective

Exploring the Selective Mechanism of Inhibitors Towards Different Subtypes of Class I PI3K

Understanding the Selectivity of Inhibitors Toward PI4KIIIα and PI4KIIIβ Based Molecular Modeling

Development of small-molecule inhibitors that target PI3Kβ

Development of small-molecule inhibitors that target PI3K13

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Study on improving the selectivity of compounds that inhibit two PI3Ks (gamma and delta)

A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR

A Selectivity Study On Mtor/Pi3k Alpha Inhibitors By Homology Modeling And 3d-Qsar

Identification of novel inhibitors targeting PI3Kα via ensemble-based virtual screening method, biological evaluation and molecular dynamics simulation

Theoretical Studies on Beta and Delta Isoform-Specific Binding Mechanisms of Phosphoinositide 3-Kinase Inhibitors.

Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.

Developing new PI3Kγ inhibitors by combining pharmacophore modeling, molecular dynamic simulation, molecular docking, fragment-based drug design, and virtual screening

Targeting Phosphatidylinositol 3‐kinase Gamma (pi3kγ): Discovery and Development of Its Selective Inhibitors

Exploring PI3Kγ binding preference with Eganelisib, Duvelisib, and Idelalisib via energetic, pharmacophore and dissociation pathway analyses

Cryo-EM structures reveal two allosteric inhibition modes of PI3Kα H1047R involving a re-shaping of the activation loop

Cryo-EM structures of PI3K reveal conformational changes during inhibition and activation

Cryo-EM Structures Reveal Two Allosteric Inhibition Modes of PI3KαH1047R Involving a Re-Shaping of the Activation Loop

Ensemble-based Virtual Screening of Human PI4KIIIα Inhibitors Toward the Hepatitis C Virus

Advances in Subunits of PI3K Class I in Cancer.

A deep learning-based theoretical protocol to identify potentially isoform-selective PI3Kα inhibitors